- Fresenius Medical Care has achieved a growth milestone as more than 14,000 U.S.-based patients are now using its NxStage system to deliver at-home hemodialysis therapy.
- This growth has led to increased adoption from a variety of dialysis providers and fulfills the company's commitment to expanding access to and utilization of home dialysis therapy.
- The latest NxStage® Versi® HD with GuideMe Software home dialysis machine is designed to simplify treatment, make learning easier and improve the user experience.
Waltham, Massachusetts (September 4, 2024) – Fresenius Medical Care (FME), a global leader in kidney care, achieved a growth milestone with more than 14,000 U.S. patients receiving home hemodialysis (HHD) therapy using its NxStage system, both through Fresenius Kidney Care clinics and other providers. The company simultaneously launched NxStage® Versi®HD, the latest version of its home dialysis machine with GuideMe software, featuring enhancements aimed at simplifying treatment, improving ease of learning and improving the user experience. These achievements underscore the effectiveness and reliability of the NxStage system to deliver safe, high-quality care to patients in the comfort of their own home.
Between January and April 2024, the number of new HHD patients initiating treatment with NxStage in the United States increased by 18% compared to the same period in 2023. For example, in April, 927 new patients in the United States initiated HHD therapy.
“We are proud to announce these achievements in our home care division,” said Joseph Turk, executive vice president and global head of the home care division at Fresenius Medical Care. “These achievements underscore our relentless commitment to ongoing innovation that improves the lives of patients who seek safety, convenience and flexibility in home dialysis.”
Since receiving FDA clearance in 2023, the latest NxStage HHD system will: Versi®HD and GuideMe Softwareis seeing strong interest in the U.S., with large, mid-size and multiple independent dialysis providers rolling out the Versi®HD with GuideMe software.
Powered by the advanced technology of GuideMe software, Versi®HD is designed to simplify HHD treatment and improve ease of learning, skills retention and user experience for patients and caregivers. The machine's illustrated-based guidance is designed to meet a variety of patient needs through set-up, treatment and troubleshooting, improving training time and skills retention. It provides graphical walk-through guidance aimed at increasing ease of use and reliability for both patients and nurses. The interface is designed to accommodate different learning styles and improve skills retention from the first training, while static image instructions allow patients to learn any step at their own pace.
“In our practice, patients are quickly taught how to train on the Versi®HD with GuideMe software and feel comfortable by the second week of training. Even better, patients complete their training 7-10 days sooner,” said Sandra Flores, Home Therapy Registered Nurse, North Central Oklahoma City.
NxStage Versi®HD with GuideMe software is currently available in the United States with global expansion planned over the next few years. Learn more about Fresenius Medical Care's home care solutions here. Home page
